RCC trials don ’t mirror real-world experience

< p > Researchers have found that real-world metastatic renal cell cancer patients being treated with tyrosine kinase inhibitors are often sicker than subjects in clinical trials for these drugs, leading to questions about safety for use in the very patients who need the drugs in clinical practice. < /p > < p > 10/06/2015 < /p >
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news